Oncopeptides (ONCO) Stock Overview
A biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ONCO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Oncopeptides AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.30 |
| 52 Week High | SEK 6.96 |
| 52 Week Low | SEK 1.27 |
| Beta | -1.43 |
| 1 Month Change | -6.86% |
| 3 Month Change | -55.65% |
| 1 Year Change | -32.51% |
| 3 Year Change | -83.89% |
| 5 Year Change | -98.94% |
| Change since IPO | -96.97% |
Recent News & Updates
ONCO: Rights Issue And Glioblastoma Study Will Support Bullish Long Term View
Analysts have maintained their SEK fair value estimate for Oncopeptides at SEK 2.80, while fine tuning assumptions for the discount rate, profit margin, and future P/E. This reflects updated views on the company’s risk profile and earnings potential without changing the headline price target.ONCO: Rights Issue And New Studies Will Support Bullish Long Term View
Analysts have modestly adjusted their SEK price target for Oncopeptides, reflecting small refinements to discount rate, profit margin assumptions, and future P/E inputs rather than a shift in the core fair value view. What's in the News Oncopeptides plans to support the MARINA real world evidence study of Pepaxti in relapsed, refractory multiple myeloma in Germany, targeting around 50 patients across about 25 sites, with iOMEDICO as sponsor and coordinator and first patient enrolment planned for the second quarter of 2026 (Key Developments).ONCO: Rights Offering And 2025 Sales Guidance Will Support Bullish View
Analysts have kept their SEK price target for Oncopeptides effectively unchanged, pointing to stable fair value assumptions and only marginal tweaks to inputs such as the discount rate, forecast revenue growth, profit margin and future P/E multiple. What's in the News Oncopeptides has filed a follow on equity offering of Ordinary Shares, targeting SEK 200.4 million through a rights offering of 129,283,736 shares at SEK 1.55 per share (Key Developments).Recent updates
ONCO: Rights Issue And Glioblastoma Study Will Support Bullish Long Term View
Analysts have maintained their SEK fair value estimate for Oncopeptides at SEK 2.80, while fine tuning assumptions for the discount rate, profit margin, and future P/E. This reflects updated views on the company’s risk profile and earnings potential without changing the headline price target.ONCO: Rights Issue And New Studies Will Support Bullish Long Term View
Analysts have modestly adjusted their SEK price target for Oncopeptides, reflecting small refinements to discount rate, profit margin assumptions, and future P/E inputs rather than a shift in the core fair value view. What's in the News Oncopeptides plans to support the MARINA real world evidence study of Pepaxti in relapsed, refractory multiple myeloma in Germany, targeting around 50 patients across about 25 sites, with iOMEDICO as sponsor and coordinator and first patient enrolment planned for the second quarter of 2026 (Key Developments).ONCO: Rights Offering And 2025 Sales Guidance Will Support Bullish View
Analysts have kept their SEK price target for Oncopeptides effectively unchanged, pointing to stable fair value assumptions and only marginal tweaks to inputs such as the discount rate, forecast revenue growth, profit margin and future P/E multiple. What's in the News Oncopeptides has filed a follow on equity offering of Ordinary Shares, targeting SEK 200.4 million through a rights offering of 129,283,736 shares at SEK 1.55 per share (Key Developments).ONCO: Rights Issue And 2025 Sales Outlook Will Support Bullish View
Analysts have adjusted their price target on Oncopeptides to SEK 2.80. The change is largely tied to updated assumptions around the discount rate, profit margin, and future P/E, rather than a shift in estimated fair value.ONCO: Rights Issue And 2025 Sales Guidance Will Support Bullish Outlook
Analysts have trimmed their price target on Oncopeptides to SEK 2.80 from SEK 4.75, reflecting updated assumptions for slightly lower revenue growth, a marginally softer profit margin, a higher discount rate, and a reduced future P/E multiple. What's in the News Oncopeptides AB (publ) has filed a follow on equity offering of approximately SEK 200.4m through a rights offering of 129,283,736 ordinary shares at SEK 1.55 per share (Key Developments).ONCO: Future Sales Guidance Will Support Bullish View On Upcoming Results
Analysts have cut their price target on Oncopeptides to €4.75 from €5.50, reflecting updated assumptions around revenue growth, profit margins, a higher discount rate, and a higher future P/E multiple. What's in the News Oncopeptides issued sales guidance for the fourth quarter 2025.
ONCO: NK Cell Platform Progress Will Drive Future Risk Reward Repricing
Analysts have reduced their price target for Oncopeptides from 5.0 to 4.5, reflecting a fair value adjustment driven by shifts in projected revenue growth, higher discount rates, stronger profit margin assumptions, and a lower future P/E estimate. What's in the News Oncopeptides issued sales guidance for the fourth quarter and full year 2025, with expected Q4 2025 net sales of SEK 18.6 million and full year 2025 net sales of SEK 71.2 million, both described by the company as higher compared with 2024 (Corporate guidance).ONCO: NK Cell Platform Progress And Expert Guidance Will Shape Future Risk Reward
Analysts have modestly lowered their future P/E assumption for Oncopeptides from 38.59x to 36.58x, keeping fair value at €5.00. They have fine tuned expectations for revenue growth and profit margins while making a slight adjustment to the discount rate.
ONCO: Improved Profitability And NK Cell Platform Will Drive Long-Term Upside
Analysts have raised their price target on Oncopeptides from approximately SEK 4.50 to SEK 5.50 per share, citing expectations of stronger long term profitability, supported by higher projected profit margins and a lower future price to earnings multiple, despite slightly tempered revenue growth assumptions and a modestly higher discount rate. What's in the News Panel of leading multiple myeloma experts publishes clinical recommendations in Annals of Hematology on optimal use of Pepaxti (melflufen), reinforcing its role as an important option for relapsed, refractory multiple myeloma, including elderly and high risk patients, with a manageable safety profile (company announcement).ONCO: Future NK Platform And Equity Raise Will Shape Risk Reward Profile
Analysts have modestly raised their price target on Oncopeptides to align with a fair value approaching $5.00 per share, citing a higher required discount rate, more conservative revenue growth and margin assumptions, and a structurally higher future P/E multiple. Taken together, these factors imply a more cautiously optimistic risk reward profile.Agreements In Europe And Japan Will Unlock Global Markets
The notable increase in Oncopeptides' fair value target is primarily driven by a higher forecasted future P/E multiple, despite a marginal dip in revenue growth expectations, with the analyst consensus price target rising from SEK2.73 to SEK3.25. What's in the News Strategic partnership with SD Pharma enhances Pepaxti's hospital reach in Spain without upfront costs, starting Q3 2025.A Look At The Fair Value Of Oncopeptides AB (publ) (STO:ONCO)
Jul 28
Agreements In Europe And Japan Will Unlock Global Markets
Strategic agreements in Europe and potential licensing in Japan will unlock major markets, enhancing future earnings and revenue growth.An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued
Jun 18Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely
Feb 29Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?
Nov 14We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully
Jul 26Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?
Mar 25Shareholder Returns
| ONCO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -2.4% | 3.2% | -1.9% |
| 1Y | -32.5% | 19.7% | 11.0% |
Return vs Industry: ONCO underperformed the Swedish Biotechs industry which returned 21.5% over the past year.
Return vs Market: ONCO underperformed the Swedish Market which returned 12.4% over the past year.
Price Volatility
| ONCO volatility | |
|---|---|
| ONCO Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.8% |
Stable Share Price: ONCO's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ONCO's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 75 | Sofia Heigis | www.oncopeptides.com/sv |
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells.
Oncopeptides AB (publ) Fundamentals Summary
| ONCO fundamental statistics | |
|---|---|
| Market cap | SEK 515.45m |
| Earnings (TTM) | -SEK 249.58m |
| Revenue (TTM) | SEK 71.12m |
Is ONCO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONCO income statement (TTM) | |
|---|---|
| Revenue | SEK 71.12m |
| Cost of Revenue | SEK 2.45m |
| Gross Profit | SEK 68.67m |
| Other Expenses | SEK 318.25m |
| Earnings | -SEK 249.58m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 13, 2026
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 96.55% |
| Net Profit Margin | -350.94% |
| Debt/Equity Ratio | -215.1% |
How did ONCO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/02 15:29 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oncopeptides AB (publ) is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Patrik Ling | DNB Carnegie |
| Erik Hultgård | DNB Carnegie |